SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds
SINTX Technologies (NASDAQ: SINT), a biomedical ceramics company, has announced the successful exercise of warrants resulting in $3.8 million in gross proceeds. The transaction involves the immediate exercise of warrants to purchase 1,099,431 shares at $3.32 per share, originally issued in February 2025.
In exchange for the exercise, the company will issue new unregistered warrants for 1,649,147 shares with an exercise price of $4.79 per share, exercisable immediately with a 5.5-year expiration. H.C. Wainwright & Co. serves as the exclusive placement agent, and SINTX plans to use the proceeds for working capital purposes.
SINTX Technologies (NASDAQ: SINT), societ脿 di ceramiche biomedicali, ha annunciato l'esercuzione con successo di warrant che ha generato 3,8 milioni di dollari di proventi lordi. L'operazione riguarda l'immediato esercizio di warrant per l'acquisto di 1.099.431 azioni a 3,32 $ per azione, emessi originariamente nel febbraio 2025.
In cambio dell'esercizio, la societ脿 emetter脿 nuovi warrant non registrati relativi a 1.649.147 azioni con prezzo di esercizio di 4,79 $ per azione, esercitabili immediatamente e con scadenza a 5,5 anni. H.C. Wainwright & Co. 猫 l'esclusivo placement agent e SINTX intende utilizzare i proventi per capitale circolante.
SINTX Technologies (NASDAQ: SINT), una compa帽铆a de cer谩micas biom茅dicas, ha anunciado el ejercicio exitoso de warrants que ha resultado en 3,8 millones de d贸lares de ingresos brutos. La transacci贸n implica el ejercicio inmediato de warrants para comprar 1.099.431 acciones a 3,32 $ por acci贸n, emitidos originalmente en febrero de 2025.
Como contraprestaci贸n por el ejercicio, la compa帽铆a emitir谩 nuevos warrants no registrados por 1.649.147 acciones con un precio de ejercicio de 4,79 $ por acci贸n, ejercitables de inmediato y con vencimiento a 5,5 a帽os. H.C. Wainwright & Co. act煤a como agente colocador exclusivo y SINTX planea usar los ingresos para capital de trabajo.
SINTX Technologies (NASDAQ: SINT), 靸濎泊 靹鸽澕氙� 旮办梾鞚� 380毵� 雼煬鞚� 齑� 靾橃澋鞚� 彀届稖頃橂姅 鞗岆煱韸� 頄夓偓鞐� 靹标车頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 瓯半灅電� 2025雲� 2鞗旍棎 氚滍枆霅� 鞗岆煱韸胳潣 歃夓嫓 頄夓偓毳� 韱淀暣 1,099,431欤�毳� 欤茧嫻 3.32雼煬鞐� 毵れ垬頃橂姅 雮挫毄鞚� 韽暔頃╇媹雼�.
頄夓偓 雽�臧�搿� 須岇偓電� 1,649,147欤�鞐� 雽�頃� 靸� 氙鸽摫搿� 鞗岆煱韸鸽ゼ 欤茧嫻 4.79雼煬鞚� 頄夓偓臧�搿� 氚滍枆頃� 鞓堨爼鞚措┌, 歃夓嫓 頄夓偓 臧�電ロ晿瓿� 毵岅赴電� 5.5雲勳瀰雼堧嫟. H.C. Wainwright & Co.臧� 雼弲 氚办箻 鞐愳澊鞝勴姼搿� 彀胳棳頃橂┌ SINTX電� 靾橃澋鞚� 鞖挫榿鞛愱笀鞙茧 靷毄頃� 瓿勴殟鞛呺媹雼�.
SINTX Technologies (NASDAQ: SINT), soci茅t茅 de c茅ramiques biom茅dicales, a annonc茅 l'exercice r茅ussi de warrants ayant g茅n茅r茅 3,8 millions de dollars de produits bruts. La transaction implique l'exercice imm茅diat de warrants permettant d'acheter 1 099 431 actions 脿 3,32 $ par action, initialement 茅mis en f茅vrier 2025.
En contrepartie de l'exercice, la soci茅t茅 茅mettra de nouveaux warrants non enregistr茅s portant sur 1 649 147 actions avec un prix d'exercice de 4,79 $ par action, exer莽ables imm茅diatement et arrivant 脿 茅ch茅ance dans 5,5 ans. H.C. Wainwright & Co. agit en tant qu'agent de placement exclusif et SINTX pr茅voit d'utiliser les produits pour le fonds de roulement.
SINTX Technologies (NASDAQ: SINT), ein Unternehmen f眉r biomedizinische Keramik, hat die erfolgreiche Aus眉bung von Warrants angek眉ndigt, die 3,8 Millionen US-Dollar Bruttoerl枚s einbrachte. Die Transaktion betrifft die sofortige Aus眉bung von Warrants zum Kauf von 1.099.431 Aktien zu 3,32 $ pro Aktie, urspr眉nglich ausgegeben im Februar 2025.
Im Gegenzug wird das Unternehmen neue nicht registrierte Warrants f眉r 1.649.147 Aktien mit einem Aus眉bungspreis von 4,79 $ pro Aktie ausgeben, die sofort aus眉bbar sind und eine Laufzeit von 5,5 Jahren haben. H.C. Wainwright & Co. fungiert als exklusiver Placement-Agent, und SINTX beabsichtigt, die Erl枚se f眉r das Umlaufverm枚gen zu verwenden.
- Secured immediate capital injection of $3.8 million through warrant exercise
- New warrants issued at $4.79 per share, representing a 44% premium to previous warrant price
- Strengthened working capital position for operations
- Additional share dilution through issuance of 1,099,431 new shares
- Potential future dilution from 1,649,147 new warrant shares if exercised
Insights
SINTX secured $3.8M through warrant exercise, strengthening its financial position while issuing new warrants with favorable terms.
SINTX Technologies has successfully completed a financial maneuver that will inject
This transaction appears strategically beneficial for SINTX. First, it provides immediate capital without diluting shareholders beyond what was already potentially dilutive from the original warrants. Second, the new warrants come with a substantially higher exercise price, meaning any future exercises will bring in capital at more favorable terms. The company specifically stated the proceeds will be used for working capital purposes, suggesting this funding will support ongoing operations rather than a specific strategic initiative.
For SINTX, a biomedical ceramics innovator specializing in silicon nitride applications, securing working capital is crucial for continued R&D and commercialization efforts. The transaction was facilitated by H.C. Wainwright & Co., a boutique investment bank that frequently works with smaller publicly traded companies. The deal's structure, with immediate cash inflow plus potential for additional future capital through the new warrants, provides SINTX with improved financial flexibility while setting terms that would only result in additional dilution at a higher valuation point.
SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (鈥淪INTX鈥� or the 鈥淐ompany鈥�), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si鈧僋鈧�), today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,099,431 shares of common stock of the Company originally issued in February 2025, having an exercise price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
In consideration for the immediate exercise of the warrants for cash and the payment of additional
The gross proceeds to the Company from the exercise of the warrants and issuance of the new warrants are expected to be approximately
The offering is expected to close on or about September 9, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital purposes.
The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the 鈥�1933 Act鈥�) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (鈥淪EC鈥�) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About SINTX Technologies, Inc.
Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Through innovation and strategic partnerships, SINTX continues to expand its portfolio across multiple markets. For more information on SINTX Technologies or its materials platform, visit聽.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, and the anticipated use of proceeds from offering. Forward-looking statements are based on management鈥檚 current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, the Company鈥檚 ability to successfully develop, manufacture, and commercialize new products; regulatory approvals; competition; market acceptance; intellectual property protection; and other factors described in the Company鈥檚 Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in its other filings with the SEC. SINTX undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.
Business and Media Inquiries for SINTX:
Elliot Sloane
ThroughCo Communications
917-291-0833
Katie Russo
ThroughCo Communications
501-282-5069
SINTX Technologies, Inc.
801.839.3502
FAQ
How much capital did SINTX Technologies (SINT) raise from the warrant exercise?
What is the exercise price of SINTX's new warrants issued in September 2025?
How many new shares will be issued from SINTX's warrant exercise?
How will SINTX Technologies use the proceeds from the warrant exercise?
Who is the placement agent for SINTX's warrant exercise transaction?
